The Outlook for Contract Services: Is That Light at the End of the Tunnel?

The expansion of the Kentucky site accounts for $80 million of the announced investment, with the remaining money earmarked for facilities in Michigan.

In this episode, Sergey Vlasenko from Agilent chats about bio/pharmaceutical manufacturing trends, with a particular focus on oligonucleotides.

The new building expands on the company’s supply chain solutions for biologics and temperature-sensitive pharmaceuticals.

In this episode, Hanns-Christian Mahler and Andrea Allmendinger from ten23 health will discuss some key aspects of biologic drug development and manufacturing.

Cambridge Healthcare Innovations says its dry powder inhaler engine, Quattrii, can deliver large volumes of biologic and mRNA molecules in a single inhalation.

The department’s newly announced partnerships were part of a weeklong visit that included discussions held at BIO 2025.